IDIBELL and ICO participate in the discovery of a weakness that could be used to treat defective cancers for SMARCA4

by Hospital Universitari de Bellvitge

The study suggests that tumors with a genetically inactivated form of the chromatin remodeling protein SMARCA4 are highly sensitive to inhibitors of the KDM6 family of histone demethylases.

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio preclínico mejora el tratami...

by CIMA - Centro de Investigación Médica Aplicada

Investigadores del Cima Universidad de Navarra constatan que la combin...

Photos Stream